Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 945
Gene Symbol: CD33
CD33
0.400 AlteredExpression disease BEFREE High CD33 expression in acute myeloid leukemia (AML) with mutated <i>NPM1</i> provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. 31851556 2020
Entrez Id: 3563
Gene Symbol: IL3RA
IL3RA
0.100 AlteredExpression disease BEFREE It has been reported that <i>FUS-ERG</i>-positive AML expresses CD123, a marker of LSC, in some cases. 31850234 2019
Entrez Id: 4853
Gene Symbol: NOTCH2
NOTCH2
0.330 AlteredExpression disease BEFREE Moreover, combining AZA with the Notch inhibitor, RO4929097, decreased the expression of Notch1and Notch2, and downstream HES1 and HEY1, which rendered AML cells insensitive to AZA-induced apoptosis and alleviated AZA-mediated cytotoxicity in AML. 31849658 2019
Entrez Id: 23462
Gene Symbol: HEY1
HEY1
0.010 Biomarker disease BEFREE Moreover, combining AZA with the Notch inhibitor, RO4929097, decreased the expression of Notch1and Notch2, and downstream HES1 and HEY1, which rendered AML cells insensitive to AZA-induced apoptosis and alleviated AZA-mediated cytotoxicity in AML. 31849658 2019
Entrez Id: 4851
Gene Symbol: NOTCH1
NOTCH1
0.100 AlteredExpression disease BEFREE Based on TCGA database, PRKD2 was found to be positively correlated with Notch1 expression, cytogenetic risk status and poorer prognosis in AML. 31849496 2019
Entrez Id: 25865
Gene Symbol: PRKD2
PRKD2
0.010 AlteredExpression disease BEFREE Based on TCGA database, PRKD2 was found to be positively correlated with Notch1 expression, cytogenetic risk status and poorer prognosis in AML. 31849496 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Advances in the understanding of the complex mechanisms of AML leukemogenesis have led to the development and recent US Food and Drug Administration (FDA) approval of several targeted therapies: midostaurin and gilteritinib targeting activated FLT3, and ivosidenib and enasidenib targeting mutated IDH1/2. 31848884 2020
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.700 Biomarker disease BEFREE Advances in the understanding of the complex mechanisms of AML leukemogenesis have led to the development and recent US Food and Drug Administration (FDA) approval of several targeted therapies: midostaurin and gilteritinib targeting activated FLT3, and ivosidenib and enasidenib targeting mutated IDH1/2. 31848884 2020
Entrez Id: 7099
Gene Symbol: TLR4
TLR4
0.070 Biomarker disease BEFREE This study aimed to assess whether genetic variants of dendritic cell-associated C-type lectine-1 (Dectin-1), Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), and myeloid differentiation primary response 88 (MyD88) influence the susceptibility to pulmonary invasive fungal disease (IFD) in patients with acute myeloid leukemia (AML) from a Chinese Han population. 31845221 2019
Entrez Id: 7097
Gene Symbol: TLR2
TLR2
0.070 Biomarker disease BEFREE This study aimed to assess whether genetic variants of dendritic cell-associated C-type lectine-1 (Dectin-1), Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), and myeloid differentiation primary response 88 (MyD88) influence the susceptibility to pulmonary invasive fungal disease (IFD) in patients with acute myeloid leukemia (AML) from a Chinese Han population. 31845221 2019
Entrez Id: 64581
Gene Symbol: CLEC7A
CLEC7A
0.020 GeneticVariation disease BEFREE In conclusion, two Dectin-1 SNPs (rs3901533 and rs7309123) are associated with increased susceptibility to pulmonary IFD in AML patients in a Chinese Han population. 31845221 2019
Entrez Id: 4615
Gene Symbol: MYD88
MYD88
0.010 Biomarker disease BEFREE This study aimed to assess whether genetic variants of dendritic cell-associated C-type lectine-1 (Dectin-1), Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), and myeloid differentiation primary response 88 (MyD88) influence the susceptibility to pulmonary invasive fungal disease (IFD) in patients with acute myeloid leukemia (AML) from a Chinese Han population. 31845221 2019
Entrez Id: 693167
Gene Symbol: MIR582
MIR582
0.010 Biomarker disease BEFREE This study aimed to reveal the biological function of miR-582-3p in acute myeloid leukemia (AML), which is one of the most frequently diagnosed hematological malignancies. 31844417 2019
Entrez Id: 22943
Gene Symbol: DKK1
DKK1
0.040 AlteredExpression disease BEFREE Colony-forming units (CFU) and expression of dickkopf-1 (DKK1), a hematopoietic inhibiting factor associated with pathogenesis of AML, were determined in CD34<sup>+</sup> HSCs, as well as the extents of JAK2 and STAT3 phosphorylation and LDOC1 expression. 31842997 2019
Entrez Id: 23641
Gene Symbol: LDOC1
LDOC1
0.010 Biomarker disease BEFREE In addition, exosomes released by AML cells targeted CD34<sup>+</sup> HSCs to decrease the expression of CFU and increase the expression of DKK1. miR-4532 was delivered into CD34<sup>+</sup> HSCs to target LDOC1 via AML cell-released exosomes. 31842997 2019
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.700 GeneticVariation disease BEFREE From a phase 1 study of 258 patients with IDH1-mutant advanced hematologic malignancies, we report results for 34 patients with newly diagnosed acute myeloid leukemia (AML) ineligible for standard therapy who received ivosidenib 500 mg once daily. 31841594 2020
Entrez Id: 3164
Gene Symbol: NR4A1
NR4A1
0.100 AlteredExpression disease BEFREE Moreover, fenretinide also exhibited an anti-leukemic effect and induced NR4A1 expression in the AML mouse model. 31839811 2019
Entrez Id: 3784
Gene Symbol: KCNQ1
KCNQ1
0.120 Biomarker disease BEFREE The aim is to explore the role of lncRNA potassium voltage-gated channel subfamily Q member 1 overlapping transcript 1 (KCNQ1OT1) and associated novel mechanisms in the progression and chemoresistance of AML. 31837329 2020
Entrez Id: 406968
Gene Symbol: MIR193A
MIR193A
0.040 AlteredExpression disease BEFREE KCNQ1OT1 aggravates AML progression and chemoresistance to ADR by inducing Tspan3 expression via adsorbing miR-193a-3p in ADR resistant AML cells, providing a theoretical basis for the treatment of AML with chemoresistance. 31837329 2020
Entrez Id: 10099
Gene Symbol: TSPAN3
TSPAN3
0.030 AlteredExpression disease BEFREE KCNQ1OT1 aggravates AML progression and chemoresistance to ADR by inducing Tspan3 expression via adsorbing miR-193a-3p in ADR resistant AML cells, providing a theoretical basis for the treatment of AML with chemoresistance. 31837329 2020
Entrez Id: 10984
Gene Symbol: KCNQ1OT1
KCNQ1OT1
0.020 Biomarker disease BEFREE The aim is to explore the role of lncRNA potassium voltage-gated channel subfamily Q member 1 overlapping transcript 1 (KCNQ1OT1) and associated novel mechanisms in the progression and chemoresistance of AML. 31837329 2020
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.700 GeneticVariation disease BEFREE IDH1 mutations are closely related to the development and progression of various human cancers, such as glioblastoma, sarcoma, and acute myeloid leukemia. 31836442 2020
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Here, we show that the triple combination of the differentiating agent retinoic acid (RA), the ER stress-inducing drug tunicamycin (Tm), and arsenic trioxide (ATO), able to generate oxidative stress, leads to the death of AML cell lines expressing fusion proteins involving the gene MLL and the internal tandem duplication (ITD) in the FLT3 tyrosine kinase receptor. 31834935 2019
Entrez Id: 4297
Gene Symbol: KMT2A
KMT2A
0.600 Biomarker disease BEFREE Here, we show that the triple combination of the differentiating agent retinoic acid (RA), the ER stress-inducing drug tunicamycin (Tm), and arsenic trioxide (ATO), able to generate oxidative stress, leads to the death of AML cell lines expressing fusion proteins involving the gene MLL and the internal tandem duplication (ITD) in the FLT3 tyrosine kinase receptor. 31834935 2019
Entrez Id: 4914
Gene Symbol: NTRK1
NTRK1
0.100 GeneticVariation disease BEFREE Here, we show that the triple combination of the differentiating agent retinoic acid (RA), the ER stress-inducing drug tunicamycin (Tm), and arsenic trioxide (ATO), able to generate oxidative stress, leads to the death of AML cell lines expressing fusion proteins involving the gene MLL and the internal tandem duplication (ITD) in the FLT3 tyrosine kinase receptor. 31834935 2019